Comparison of acute toxicity and mortality after two different dosing regimens of high-dose interleukin-2 for patients with metastatic melanoma
- 343 Downloads
We compared acute toxicity, drug exposure, in-hospital mortality, and inpatient length of stay between two currently recommended dosing protocols (from the National Comprehensive Cancer Network Guidelines) of high-dose interleukin-2 (IL-2) treatment for patients with metastatic melanoma. Patients with metastatic melanoma who received high-dose IL-2 treatment between 2003 and 2010 were identified. Chemotherapy orders, electronic medical records, paper medical charts, and patient discharge summaries were reviewed retrospectively. We identified 13 patients who had received 600,000 units/kilogram (kg)/dose and 15 patients who had received 720,000 units/kg/dose. Patients in the 720,000 units/kg/dose group had a higher rate of grade 3 and 4 bilirubin elevations (34 vs. 12 %), weight gain (any grade, 96 vs. 89 %), and thrombocytopenia (any grade, 75 vs. 65 %). Patients receiving the higher dose also experienced more dose-limiting neurotoxicity (45 vs. 23 %), large-volume diarrhea (15 vs. 0 %), and hepatotoxicity (7 vs. 0 %). There was no in-hospital mortality during treatment in either group. The average length of stay was similar between both groups (5 days, SD = 1 for both groups), and the median cumulative IL-2 exposure was similar between both groups for the first course (10.1 vs.10.5 million units/kg) and for all courses (approximately 11–12 million units/kg). Both high-dose IL-2 protocols had comparable in-hospital mortality and cumulative IL-2 exposure. The 720,000 units/kg/dose dosing scheme did not shorten the length of stay but did lead to greater acute toxicity. Therefore, as a result, we recommend 600,000 units/kg/dose when deciding between the two regimens.
KeywordsHigh dose Interleukin-2 Metastatic Melanoma Toxicity
Conflict of interest
This research was not funded by any organization and the authors have no conflicts to disclose in regards to funding of this research. Additional potential conflict of interest information has been completed and submitted by each author and is attached in this submission.
- 1.NCCN Clinical Practice Guidelines in Oncology (2013) Melanoma. Version 2.2013. http://nccn.org. Accessed 6 February
- 2.American Cancer Society (2013) Melanoma skin cancer. http://www.cancer.org/Cancer/SkinCancer-Melanoma/DetailedGuide/index. Accessed 6 February
- 3.DeVita VT, Lawrence TS, Rosenberg SA and DePinho RA (2008) Cutaneous melanoma. In: DeVita V, Lawrence T, and Rosenberg S (eds) Cancer: principles and practice of oncology, 8th edn. Lippincott Williams and Wilkins, Philadelphia, pp 1897–1951Google Scholar
- 11.Atkins MB, Hsu J, Lee S et al (2008) Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 26:5748–5754PubMedCentralPubMedCrossRefGoogle Scholar
- 14.Bhatia S, Tykodi SS, Thompson JA (2009) Treatment of metastatic melanoma: an overview. Oncology (Williston Park) 23:488–496Google Scholar
- 15.Aldesleukin (Proleukin) package insert (2009) Novartis Pharmaceuticals Corporations, East Hanover, NJGoogle Scholar
- 16.DeVita VT, Lawrence TS, Rosenberg SA and DePinho RA (2008) Interleukin therapy. In: DeVita V, Lawrence T, and Rosenberg S (eds) Cancer: principles and practice of oncology, 8th edn. Lippincott Williams and Wilkins, Philadelphia, pp 1897–1951Google Scholar
- 17.DeVita VT, Lawrence TS, Rosenberg SA and DePinho RA (2005) Interleukin-2. In: DeVita V, Lawrence T, and Rosenberg S (eds) Cancer: principles and practice of oncology, 7th edn. Lippincott Williams and Wilkins, Philadelphia, pp 431–438Google Scholar
- 21.Cancer Therapy Evaluation Program (2010) Common terminology criteria for adverse events, version 3.0, DCTD, NCI, NIH, DHHS March 31, 2003. August 9, 2006, http://ctep.cancer.gov. Accessed 15 March
- 22.Nafcillin. Drugdex®. Thomson Micromedex. Greenwood Village, CO. http://www.thomsonhc.com/hcs/librarian. Accessed 20 June 2010